as informed in thestar
Eric Hoskins announces free shingles vaccine for seniors
Eric Hoskins announces free shingles vaccine for seniors
Ontario seniors between the ages of 65 and 70 can now get the vaccine to prevent shingles at no charge, saving $170 and likely preventing a case of the painful skin disease.Health Minister Eric Hoskins made the announcement Thursday at a west-end seniors centre, saying the shots are the best way to avoid the painful rashes that come with the malady, which is related to chickenpox.He called it "chickenpox, part two" and noted "it comes back and it's much worse."The vaccination program, promised in the government's spring budget, will cost $68 million over three years for almost 1 million eligible seniors.
in the same way digitallook
GlaxoSmithKline's shingles vaccine proves highly effective
GlaxoSmithKline's shingles vaccine proves highly effective
Oliver Haill | Sharecast | 15 Sep, 2016 07:40 - Updated: 08:53 | | |GlaxoSmithKline 1,624.000.65% 10.50 Max: 1,625.82Min: 1,607.00 Volume: 7,123,344MM 200 : n/a 17:30 15/09/16 FTSE 100 6,730.300.85% 56.99 Max: 6,736.84Min: 6,654.82 Volume: 0MM 200 : n/a 17:30 15/09/16 TechMARK 3,471.700.60% 20.74 Max: 3,472.73Min: 3,439.93 Volume: 0MM 200 : n/a 17:30 15/09/16 FTSEurofirst 300 1,339.130.44% 5.88 Max: 1,340.02Min: 1,328.95 Volume: 0MM 200 : n/a 17:30 15/09/16 Pharmaceuticals & Biotechnology 14,420.610.85% 121.55 Max: 14,432.10Min: 14,204.01 Volume: 0MM 200 : n/a 17:30 15/09/16 FTSE 350 3,730.310.83% 30.56 Max: 3,733.68Min: 3,690.33 Volume: 0MM 200 : n/a 17:19 15/09/16 FTSE All-Share 3,674.940.80% 29.14 Max: 3,678.15Min: 3,636.80 Volume: 0MM 200 : n/a 17:19 15/09/16After its Shingrix shingles vaccine proved extremely successful in a trial among elderly patients, GlaxoSmithKline has begun planning regulatory applications for later this year.In a Phase III study on adults 70 years' old or above, two doses of Shingrix showed 90% efficiency compared to placebo.Efficacy was maintained with an 88% reduction in the risk of shingles in the fourth year after vaccination.
as well foxnews
GSK shingles vaccine remains effective after 4 years: study
GSK shingles vaccine remains effective after 4 years: study
GlaxoSmithKline's experimental vaccine to prevent the intensely painful condition known as shingles remained 90 percent effective in people over age 70 even four years after receiving the injection, according to data published on Wednesday.In clinical trials, GSK's Shingrix has shown greater protection for older recipients than what has been demonstrated by Merck & Co's rival Zostavax vaccine.The drug is one of GSK's biggest new product hopes.
by the same token on proactiveinvestors
GlaxoSmithKline PLC shingles vaccine shown to last four years in elderly patients
GlaxoSmithKline PLC shingles vaccine shown to last four years in elderly patients
Shingrix showed a greater level of protection than its rivalIn a phase III study published in the New England Journal of Medicine, Shingrix showed a 90% efficacy in adults aged 70 and older that was maintained for four years.Pharma giant PLC ( ) has shown that its shingles vaccine Shingrix remained effective in elderly patients after four years.In a phase III study published in the New England Journal of Medicine, Shingrix showed a 90% efficacy in adults aged 70 and older that was maintained for four years.
No comments:
Post a Comment